The combination of accelerating revenue growth, margin expansion, and raised guidance suggests strong commercial momentum. Traders should monitor whether future quarters show progress toward narrowing Adjusted EBITDA losses as revenue scales.
Price Chart
Executive Summary
Kestra Medical Technologies reported strong Q3 FY26 financial results with revenue of $24.6 million, up 63% year-over-year, and raised full-year revenue guidance to $93 million. Gross margin expanded to 52.6%, driven by volume leverage and a favorable patient mix, though the company continues to report significant net losses due to heavy investment in commercial expansion.
Key Financial Metrics
Key Facts
- Q3 FY26 revenue was $24.6 million, a 63% increase year-over-year
- Gross margin expanded to 52.6% from 43.4% in the prior year period
- Company raised FY26 revenue guidance to $93 million, up from $91 million and initial guidance of $85 million
- 5,462 prescriptions for ASSURE® system, up 58% YoY
- Cash and cash equivalents totaled $291 million, bolstered by recent public offering
- Adjusted EBITDA loss was $21.2 million, widened from $16.3 million in prior year
Financial Impact
Revenue growth accelerating to 63% YoY in Q3 with margin expansion; full-year revenue guidance increased to $93 million (55% growth)
Risk Factors
- Continued widening of operating losses despite revenue growth, with GAAP net loss increasing to $34.2 million
- Heavy reliance on continued market adoption of the ASSURE® system and favorable reimbursement trends
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257636 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Insider Cluster | $28.76 | awaiting T+20 | — | $29.88 (+3.88%) |
Oct 20, 2026 6d ago | 144 | $27.31 | awaiting T+20 | — | $29.88 (+9.39%) |
Oct 20, 2026 7d ago | ANALYST-UPGRADE | $28.28 | awaiting T+20 | — | $29.88 (+5.64%) |
Sep 30, 2026 26d ago | 144 | $27.12 | awaiting T+20 | — | $29.88 (+10.18%) |
Sep 14, 2026 6w ago | Press Release | $25.18 $26.97 | ▲ +7.11% | ▲ +4.39% | $29.88 (+18.65%) |
Sep 10, 2026 6w ago | Insider Cluster | $22.85 $26.98 | ▲ +18.07% | ▲ +16.21% | $29.88 (+30.74%) |
Sep 10, 2026 6w ago | Press Release | $23.57 $25.77 | ▲ +9.33% | ▲ +7.21% | $29.88 (+26.75%) |
Aug 31, 2026 8w ago | Press Release | $25.12 $28.29 | ▲ +12.62% | ▲ +12.30% | $29.88 (+18.93%) |
Aug 26, 2026 8w ago | Press Release | $26.57 $25.76 | ▼ −3.05% | ▼ −3.27% | $29.88 (+12.44%) |
Aug 11, 2026 10w ago | Insider Cluster | $28.00 $23.57 | ▲ +15.82% | ▲ +13.92% | $29.88 (−6.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers